Robert A. Bradway

New Capabilities

Leading Amgen's oncology expansion strategy

For decades, patients with extensive-stage small-cell lung cancer who relapsed after chemotherapy had almost nowhere to turn — five-year survival rates sat around 3%. Now a drug that physically bridges the patient's own immune cells to their tumor cells has been approved in both the United States and China, opening a new treatment class for one of the deadliest cancers. Tarlatamab, sold as Imdelltra, reduced the risk of death by 40% compared to standard chemotherapy in a confirmatory trial of 509 patients.

Updated 3 hours ago